已收盤 11-20 16:00:00 美东时间
-0.017
-4.47%
11月17日,Coherus Oncology(CHRS)收跌3.73%,报0.51美元,成交额183.65万美元,市值7818.09万美元。 行情数据 • 开...
11-17 08:08
Oncolytics Biotech and Coherus Oncology have entered a clinical supply agreement to evaluate the combination of pelareorep and toripalimab in patients with squamous cell anal carcinoma (SCAC). The study aims to assess whether pelareorep's immune activation mechanisms can enhance the antitumor activity of toripalimab in patients who have progressed on first-line treatment. Pelareorep stimulates antitumor immune responses, while toripalimab blocks ...
11-13 17:10
今日重点评级关注:花旗:维持Faeth Therapeutics"买入"评级,目标价从55美元升至60美元;HC Wainwright & Co.:维持Ocular Therapeutix"买入"评级,目标价从25美元升至28美元
11-11 10:50
Coherus Oncology shares are trading lower after the company reported worse-than-expected Q3 sales results.
11-11 02:05
Guggenheim analyst Paul Jeng maintains Coherus Oncology (NASDAQ:CHRS) with a Buy and lowers the price target from $10 to $8.
11-10 21:56
最新财报显示,Coherus Oncology 2026财年第3季度实现: 营业收入:1427.4万美元 同比:增长23.36% 净利润:-3933.4万美元...
11-10 17:00
11月10日,Coherus Oncology(CHRS)收涨6.18%,报0.82美元,成交额180.26万美元,市值1.26亿美元。 行情数据 • 开盘价...
11-10 07:56
Coherus BioSciences (NASDAQ:CHRS) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.22) by 9.09 percent. This is a 39.39 percent increase over losses of $(0.33) per share from the same period last year. The company reported quarterly sales of $14.274 mil...
11-10 05:14
11月3日,Coherus Oncology(CHRS)收跌9.72%,报0.75美元,成交额203.35万美元,市值1.16亿美元。 行情数据 • 开盘价:...
11-03 07:55
今日重点评级关注:Canaccord Genuity:维持Wave Life Sciences"买入"评级,目标价从42美元升至44美元;Canaccord Genuity:维持Pharming Group"买入"评级,目标价从38美元升至41美元
10-30 12:30